Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Available until 12/1/2024

Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now

featured
Published in Respiratory Medicine

Journal Scan / Research · October 03, 2024

Efficacy and Safety of Inhaled Colistimethate Sodium in Patients With Bronchiectasis and Pseudomonas aeruginosa Infection

The Lancet Respiratory Medicine

 

TAKE-HOME MESSAGE

abstract

This abstract is available on the publisher's site.

Access this abstract now   Full Text Available for ClinicalKey Subscribers

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Respiratory Medicine
Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months
Lancet Respir Med 2024 Sep 06;[EPub Ahead of Print], CS Haworth, M Shteinberg, K Winthrop, A Barker, F Blasi, K Dimakou, LC Morgan, AE O'Donnell, FC Ringshausen, O Sibila, RM Thomson, KJ Carroll, F Pontenani, P Castellani, JD Chalmers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading